Plasma vascular endothelial growth factor in Japanese Type 2 diabetic patients with and without nephropathy

Journal of Diabetes and its Complications

Volumn 16, Issue 6, 2002, Pages 386-390

  Shimada, K ^a   Baba, T ^a   Neugebauer, S ^a   Onozaki, A ^a   Yamada, D ^a   Midorikawa, S ^a   Sato, W ^a   Watanabe, T ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Japanese; Nephropathy; Retinopathy; Type 2 diabetes; Vascular endothelial growth factor (VEGF)

Indexed keywords

ALBUMIN; CREATININE; HEMOGLOBIN A1C; VASCULOTROPIN; ENDOTHELIAL CELL GROWTH FACTOR; GLYCOSYLATED HEMOGLOBIN; LYMPHOKINE; SIGNAL PEPTIDE; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; ENZYME IMMUNOASSAY; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; ASIAN; BLOOD; COMPARATIVE STUDY; CONFIDENCE INTERVAL; MIDDLE AGED; NONPARAMETRIC TEST;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CONFIDENCE INTERVALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENDOTHELIAL GROWTH FACTORS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; JAPAN; LYMPHOKINES; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036860254     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(02)00162-9     Document Type: Article

References (22)

1. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E., Nguyen H.V., Aiello L.M., Ferrara N., King G.L. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New England Journal of Medicine. 331:1994;1480-1487.
2. Borch-Johnsen K., Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. British Medical Journal. 294:1987;1651-1654.
3. Brooks S.E., Gu X., Kaufmann P.M., Marcus D.M., Caldwell R.B. Modulation of VEGF production by pH and glucose in retinal Muller cells. Current Eye Research. 17:1998;875-882.
4. Burgos R., Simo R., Audi L., Mateo C., Mesa J., Garcia-Ramirez M., Carrascosa A. Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy. Diabetologia. 40:1997;1107-1109.
5. Chaturvedi N., Fuller J.H., Pokrast F., Rottiers R., Papazoglou N., Aiello L.P. Circulating plasma vascular endothelial growth factor and microvascular complications of Type 1 diabetes mellitus: the influence of ACE inhibition. Diabetic Medicine. 18:2001;288-294.
6. Chiarelli F., Spagnolit A., Basciani F., Tumini S., Mezzetti A., Cipollone F., Cuccurullo F., Morgese G., Verrotti A. Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications. Diabetic Medicine. 17:2000;650-656.
7. Clermont A.C., Aiello L.P., Mori F., Ailello L.M., Bursell S.E. Vascular endothelial growth factor and severity of non-proliferative diabetic retinopathy mediate retinal haemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy. American Journal of Opthalmology. 124:1997;433-446.
8. Cooper M.E. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet. 352:1998;213-219.
9. Cooper M.E., Vranes D., Youssef S., Stacker S.A., Cox A.J., Rizkalla B., Casley D.J., Bach L.A., Kelly D.J., Gilbert R.E. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes. 48:1999;2229-2239.
10. De Vriese A., Tilton R., Elger M., Stephan C.C., Kriz W., Lameire N.H. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. Journal of the American Society of Nephrology. 12:2001;993-1000.
11. Flyvbjerg A. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia. 43:2000;1205-1223.
12. Hovind P., Tarnow L., Oestergaard P.B., Parving H.-H. Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney International. 57:2000;S56-S61.
13. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1989;1306-1309.
14. Ministry of Health, Labor, and Welfare of Japan, Part 2, Chapter 6, Section 4. Promoting lifelong health and regional health. 1998-1999 Social security and national life. Annual Report on Health and Welfare, vol. 1. Ministry of Health, Labor and Welfare, Tokyo, 2000.
15. Park S.H., Kim K.W., Lee Y.S., Baek J.H., Kim M.S., Lee Y.M., Lee M.S., Kim Y.J. Hypolgycemia-induced VEGF expression is mediated by intravcellular Ca2+ and protein kinase C signaling pathway in HepG2 human hepatoblastoma cells. International Journal of Molecular Medicine. 7:2001;91-96.
16. Punglia R.S., Lu M., Hsu J., Kuroki M., Tolentino M.J., Keough K., Levy A.P., Levy N.S., Goldberg M.A., D'Amato R.J., Adamis A.P. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes. 46:1997;1619-1626.
17. Simon M., Grone H.J., Johren O., Kullmer J., Plate K.H., Risau W., Fuchs E. Expression of vascular endothelial growth factor and its receptors in human renal oncogenesis and in adult kidney. American Journal of Physiology. 268:1995;F240-F250.
18. Sordello S., Bertarand N., Planet J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochemical and Biophysical Research Communications. 251:1998;287-290.
19. The chronic dialysis patients registry in Japan - 1991. Journal of the Japanese Society for Dialysis Therapy. 26:1993;17-23.
20. Suzuma I., Mandai M., Takagi H., Suzuma K., Otani A., Oh H., Kobayashi K., Honda Y. 17 Beta-estradiol increases VEGF receptor-2 and promotes DNA synthesis in retinal microvascular endothelial cells. Investigative Ophthalmology & Visual Science. 40:1999;2122-2129.
21. Tsuchida K., Makita Z., Yamagishi S., Atsumi T., Miyoshi H., Obara S., Ishida M., Ishikawa S., Yasumura K., Koike T. Suppression of transforming growth factor and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia. 42:1999;579-588.
22. Wasada T., Kawahara R., Katsumori K., Naruse M., Omori Y. Plasma concentration of immunoreactive vascular endothelial growth factor and its relation to smoking. Metabolism. 47:1998;27-30.